Lite Strategy (LITS) Research & Development (2010 - 2026)
Lite Strategy (LITS) posted Research & Development of $30000.0 for Q1 2026, down 34.78% on a QoQ basis from $46000.0 in Q4 2025, and down 91.87% year-over-year from $369000.0 in Q1 2025.
Analysis
Lite Strategy (LITS) Research & Development (2010 - 2026) Analysis & Trends
Lite Strategy has reported Research & Development for 17 years, with the latest figure at $30000.0 in Q1 2026.
- On a quarterly basis, Research & Development fell 91.87% year-over-year to $30000.0 in Q1 2026; TTM through Mar 2026 was $169000.0, a 97.83% decrease from a year earlier, with the FY2025 full-year figure at $3.9 million, down 76.31% from the prior year.
- Research & Development was $30000.0 for Q1 2026 at Lite Strategy, down from $46000.0 in the prior quarter.
- The five-year high for Research & Development was $22.3 million in Q1 2022, with the low at $10000.0 in Q3 2025.
- Average Research & Development over 5 years is $6.9 million, with a median of $3.5 million recorded in 2023.
- The sharpest annual moves came in 2024 and 2025: Research & Development jumped 53.46% in 2024, then slumped 99.68% in 2025.
- Over 5 years, Research & Development stood at $15.3 million in 2022, then tumbled by 74.45% to $3.9 million in 2023, then tumbled by 92.13% to $308000.0 in 2024, then slumped by 85.06% to $46000.0 in 2025, then plunged by 34.78% to $30000.0 in 2026.
- The last three Research & Development figures came in at $30000.0 (Q1 2026), $46000.0 (Q4 2025), and $10000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1.87 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 1.76 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 993.80 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.63 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -486.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 651.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 529.60 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 202.02 Mn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | 30,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 30,000.00 |
| Dec 31, 2025 | 46,000.00 |
| Sep 30, 2025 | 10,000.00 |
| Jun 30, 2025 | 83,000.00 |
| Mar 31, 2025 | 369,000.00 |
| Dec 31, 2024 | 308,000.00 |
| Sep 30, 2024 | 3.16 Mn |
| Jun 30, 2024 | 3.94 Mn |
| Mar 31, 2024 | 5.22 Mn |
| Dec 31, 2023 | 3.91 Mn |
| Sep 30, 2023 | 3.49 Mn |
| Jun 30, 2023 | 2.57 Mn |
| Mar 31, 2023 | 15.10 Mn |
| Dec 31, 2022 | 15.31 Mn |
| Sep 30, 2022 | 19.46 Mn |
| Jun 30, 2022 | 21.84 Mn |
| Mar 31, 2022 | 22.32 Mn |
| Dec 31, 2021 | 21.53 Mn |
| Sep 30, 2021 | 19.95 Mn |
| Jun 30, 2021 | 16.29 Mn |